IW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Linder 37 CFR 1.97(b) or 1.97(c))					Docket No. 19746					
In Re Application Of: Larry Ward, et al. OCT 2 6 2006										
Application No. Filing Bete Examiner Customer No. Group Art Unit Confirmation										
10/	575,928	April 14, 2006	Unassigned	23389	Unassigned	Unassigned				
Title: POXVIRUS VECTOR ENCODING RETROVIRUS (EG HIV) AND CYTOKINE										
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450										
			37 CFR 1.97(b)							
	1. Mean The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.									
			37 CFR 1.97(c)							
2.	The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:									
	the statement specified in 37 CFR 1.97(e);									
	OR									
	☐ the t	fee set forth in 37 CF	FR 1.17(p).							

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Ungle: 37 CFR 1.97(b) eq. (27(c))						Docket No. 19746			
In Re Application of: Larry D. Arrd, et al. OCT 2.5 1000 gr.									
Application No.	Group Art Unit	Confirmation No.							
10/575,928	April 14, 2006	Unassigned	l	23389	Unassigned	Unassigned			
Title: POXVIRUS VECTOR ENCODING RETROVIRUS (EG HIV) AND CYTOKINE									
	(Only cor	Payme npiete if Applicant elects	nt of Fee	ee set forth in 37	CFR 1.17(p))				
The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. Charge the amount of									
Xiaochun Zhu Registration No. 56 Scully, Scott, Murp 400 Garden City Pl Garden City, New 516-742-4343	ohy & Presser, P.C. laza, Suite 300					·			
cc:									

P10A/REV06



Applicants: Larry D. Ward, et al. Examin

Examiner: Unassigned

Serial No.: 10/575,928

Art Unit: Unassigned

April 14, 2006

Docket: 19746

Filed:

POXVIRUS VECTOR ENCODING

Dated:

October 24, 2006

RETROVIRUS (EG HIV) AND CYTOKINE

Mail Stop PCT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

- 1. PCT International Publication No. WO 00/28003, published May 18, 2000;
- Kent S.J. et al., "A Recombinant Avipoxvirus HIV-1 Vaccine Expressing Interferon-Gamma is Safe and Immunogenic in Macaques", Vaccine 18:2250-2256 (2000);
- PCT International Publication No. WO 2004/058278 A1, published July 15, 2004; and
- Jiang W. et al., "Construction and Identification of Recombinant Fowlpox Virus Coexpressing HIV-1CN gp120 and hIL-6", Chin J. Microbiol Immunol 33(6):414-417 (2003), Chemical Abstracts 141:151863.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 24, 2006

Xiaochun Zhu

The references were cited in an International Search Report dated December 21, 2004 received from the Australian Patent Office. Applicants are submitting a copy of the above-cited references. Applicants previously submitted a copy of the International Search Report on April 14, 2006. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R.§ 1.97(b), no statement or fee is required.

Respectfully submitted,

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza, Suite 300 Garden City, New York 11530 (516) 742-4343

XZ:dg

	•				Docket Number (Optional)		Application Number			
	· INFORMATION DISCLOSURE CITATION				19746 Applicant(s)	10/575,928				
	PEtse several sheets if necessary)				Larry D. Ward, et al.		Group Art Unit			
/	(Vage)				April 14, 2006			ssigned		
OCT 2.6 2000 U.S. PA					DOCUMENTS	_				
*EXAMINER INITIAL	3 6.	DOLLMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	-									
U.S. PATENT APPLICATION PUBLICATIONS										
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	SUBCLASS FILING DATE IF APPROPRIATE		
			FORE	IGN PATE	NT DOCUMENTS					
	REF	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	Tran YES	shifton NO	
/L.H./		WO 00/28003	5/18/00	PCT				1		
/L.H./		WO 2004/058278 A1	7/15/04	PCT				1		
OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.)										
/L.H.	Kent S.J. et al., "A Recombinant Avipoxvirus HIV-1 Vaccine Expressing Interferon-Gamma is Safe and Immunogenic in Macaques", Vaccine 18:2250-2256 (2000)									
/L.H./	Jiang W. et al., "Construction and Identification of Recombinant Fowlpox Virus Coexpressing HIV-ICN gp120 and bIL-Chin J. Microbiol Immunol 23(6):414-417 (2003), Chemical Abstracts 141:151863					ыL-6",				
EXAMINER /Louise Humphrey/					DATE CONSIDERED	11/02/	2009			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										
Form PTO-A820 POSAMEVOS Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE										

(also form PTO-1449)